Loading clinical trials...
Loading clinical trials...
A Randomized, Balanced, Phase 1/2A, Multiple-dose, Open-label, Two-treatment, Two-period, Two-sequence, Crossover, Relative Bioavailability Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
Conditions
Interventions
AL001
Lithium carbonate
Locations
1
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
April 1, 2026
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
April 20, 2026
NCT07494305
NCT07172516
NCT07288320
NCT07213466
NCT06804525
NCT05303064
Lead Sponsor
Alzamend Neuro, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions